TheEdgeResearch
Home / Stocks / OPHLY

Ono Pharmaceutical Co., Ltd. (OPHLY)

OTC Healthcare Drug Manufacturers - General
$5.11 ▲ +0.00%
Market Cap
$7.20B
Sector
Healthcare
Industry
Drug Manufacturers - General
Beta
0.14
52-Wk Range
4.36-5.75
CEO
Gyo Sagara
Country
JP
Currency
USD

Ono Pharmaceutical Co., Ltd. operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Osaka, OS, JP. The stock last traded at $5.11, up 0.00% on the session, giving a market capitalisation of $7.20B. On trailing twelve-month figures it carries a trailing P/E of 15.49, a net margin of 15.2%. Its beta of 0.14 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
15.49
Price / Sales
2.35
Price / Book
1.32
EV / EBITDA
7.34
Gross margin
74.1%
Operating margin
22.1%
Net margin
15.2%
Return on equity
—
Debt / equity
0.13
Current ratio
3.32
Dividend yield
3.3%
Payout ratio
50.3%
Company profile
Exchange
Other OTC
Employees
4,206
IPO date
2012-10-02
Headquarters
Osaka, OS, JP
About Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd., along with its affiliated companies, is engaged in the global development, manufacturing, procurement, and sale of a diverse range of pharmaceutical products and diagnostic tools. Its diverse oncology portfolio includes OPDIVO intravenous infusions, KYPROLIS for injection, MEKTOVI, VELEXBRU, and ADLUMIZ tablets, along with BRAFTOVI capsules, all prescribed for various malignant tumors. It also provides EMEND capsules and PROEMEND intravenous injections to alleviate chemotherapy-induced nausea and vomiting, and DEMSER capsules for managing symptoms in pheochromocytoma patients. Beyond oncology, the company's offerings span multiple therapeutic areas. For metabolic disorders, it supplies GLACTIV and FORXIGA tablets for type 2 diabetes. Cardiovascular health is supported by ONOACT injections for tachyarrhythmia, CORALAN for chronic heart failure, and OPALMON tablets addressing peripheral circulatory disorders. Autoimmune conditions like rheumatoid arthritis are treated with ORENCIA injections. Neurological therapies include RIVASTACH patches for Alzheimer's disease and ONGENTYS tablets for Parkinson's disease. Other notable products are PARSABIV intravenous injections for dialysis patients, STAYBLA tablets for overactive bladder, ONON capsules and dry syrups for bronchial asthma and allergic rhinitis, and RECALBON tablets for osteoporosis, with JOYCLU intra-articular injection available to improve joint function. Moreover, the company is heavily invested in research and development, with a pipeline targeting a wide array of diseases. This includes various malignancies such as esophageal, urothelial, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular, pancreatic, biliary tract, gastric, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, and virus-positive/negative solid tumors, as well as primary central nervous system lymphoma. Beyond cancer, its developmental efforts extend to myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative and autoimmune disorders, narcolepsy, and thrombosis. Established in 1717, the company maintains its corporate headquarters in Osaka, Japan.

Comparable companies

Ono Pharmaceutical Co., Ltd. is most often compared with the following Healthcare names:

ALPMYAMGNBIIBBMYDSNKYGILDLLYORINYOTSKYSGIOY
More research on OPHLY
OPHLY technical analysis OPHLY TheEdge Score Compare against peers
Open full interactive analysis & DCF →